Group Insurance Commission hears stewardship findings, declines major plan‑design cuts for drug and provider cost pressures

The Group Insurance Commission on Jan. 16 reviewed mid‑year stewardship reports from its carriers showing rising high‑cost claimants and prescription cost trends and discussed plan‑design changes the staff will bring forward for fiscal 2026. Commissioners approved the minutes from the December meeting and received a verbal update that the fund—s year‑to‑date deficit remains over $100 million.

Why it matters: The commission oversees health benefits for state employees, retirees and participating municipalities and is one of the state's largest purchasers of health care. Commission staff told members that the drivers of this year—s cost increases include high‑cost specialty drugs, growing use of GLP‑1 class medications, and rising hospital‑based prices, and that those pressures require purchasing‑ and market‑level fixes rather than sweeping plan‑design cuts that shift costs to members.

Executive director Matt (executive director) opened the meeting and led the executive‑director—s report outlining two recently enacted laws that affect the GIC: the PACT Act (prescription drug policy changes and expanded authority for the Health Policy Commission) and a separate law expanding market‑review authority for health care transactions. Matt noted staff will present plan‑design recommendations in February and said, “plan design is not primarily the right place to look for solutions to these much bigger and deeper problems,” a conclusion staff reached after evaluating options.

Cameron McBean, the GIC—s director of vendor management, summarized the stewardship meetings with the commission—s carriers and pharmacy benefit manager. He reported…